Vinorelbine (Navelbine®) : A third-generation vinca alkaloidBUDMAN, D. R.Cancer investigation. 1997, Vol 15, Num 5, pp 475-490, issn 0735-7907Article

Early studies of etoposide phosphate, a water-soluble prodrugBUDMAN, D. R.Seminars in oncology. 1996, Vol 23, Num 6, pp 8-14, issn 0093-7754, SUP13Article

INTERACTION OF IGE WITH RAT BASOPHILIC LEUKEMIA CELLS. V. BINDING PROPERTIES OF CELL FREE PARTICLESMETZGER H; BUDMAN D; LUCKY P et al.1976; IMMUNOCHEMISTRY; G.B.; DA. 1976; VOL. 13; NO 5; PP. 417-423; BIBL. 17 REF.Article

PHASE II TRIAL OF PYRAZOFURIN IN MALIGNANT MELANOMA.BUDMAN D; CURRIE V; WITTES R et al.1977; CANCER TREATN. REP.; U.S.A.; DA. 1977; VOL. 61; NO 9; PP. 1733-1734; BIBL. 4 REF.Article

New vinca alkaloids and related compoundsBUDMAN, D. R.Seminars in oncology. 1992, Vol 19, Num 6, pp 639-645, issn 0093-7754Article

TAMOXIFEN IN UNRESECTABLE HYPERNEPHROMA: A PHASE II TRIAL AND REVIEW OF THE LITERATUREWEISELBERG L; BUDMAN D; VINCIGUERRA V et al.1981; CANCER CLIN. TRIALS; ISSN 0190-1206; USA; DA. 1981; VOL. 4; NO 2; PP. 195-198; BIBL. 22 REF.Article

Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomesSHAPIRA, I; OSWALD, M; MASON, C et al.British journal of cancer. 2014, Vol 110, Num 4, pp 976-983, issn 0007-0920, 8 p.Article

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia : Focus on hematologyDAMLE, R. N; WASIL, T; LICHTMAN, S. M et al.Blood. 1999, Vol 94, Num 6, pp 1840-1847, issn 0006-4971Article

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancerJONES, S; WINER, E; VOGEL, C et al.Journal of clinical oncology. 1995, Vol 13, Num 10, pp 2567-2574, issn 0732-183XArticle

Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction : Cancer and leukemia group B 9565VENOOK, A. P; EGORIN, M. J; RATAIN, M. J et al.Journal of clinical oncology. 2000, Vol 18, Num 14, pp 2780-2787, issn 0732-183XArticle

Phase i and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction : Cancer and leukemia group B 9264VENOOK, A. P; EGORIN, M. J; SCHILSKY, R. L et al.Journal of clinical oncology. 1998, Vol 16, Num 5, pp 1811-1819, issn 0732-183XArticle

Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephromaSCHER, H. I; YAGODA, A; AHMED, T et al.Cancer chemotherapy and pharmacology. 1985, Vol 14, Num 1, pp 79-80, issn 0344-5704Article

Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon : a report of CALGB study 8515GOLOMB, H. M; DODGE, R; MICK, R et al.Leukemia. 1994, Vol 8, Num 12, pp 2037-2040, issn 0887-6924Article

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancerPETERS, W. P; ROSS, M; WU, K et al.Journal of clinical oncology. 1993, Vol 11, Num 6, pp 1132-1143, issn 0732-183XArticle

Phase II trial of zeniplatin (CL 286 558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapyMARKMAN, M; DEMARCO, L. C; LEWIS, J. L et al.Journal of cancer research and clinical oncology. 1993, Vol 119, Num 4, pp 234-236, issn 0171-5216Article

Phase I and clinical pharmacological evaluation of 4'-deoxydorubicin in patients with advanced cancerSTANTON, G. F; RAYMOND, V; YOUNG, C. W et al.Cancer research (Baltimore). 1985, Vol 45, Num 4, pp 1862-1868, issn 0008-5472Article

Combination chemotherapy for mestatatic or recurrent carcinoma of the breast : a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP : cancer and leukemia group B study 8281AISNER, J; CIRRINCIONE, C; HENDERSON, I. C et al.Journal of clinical oncology. 1995, Vol 13, Num 6, pp 1443-1452, issn 0732-183XArticle

Use of cisplatin for elderly patientsLICHTMAN, S. M; BUCHHOLTZ, M; BOOTHBY, R et al.Age and ageing. 1992, Vol 21, Num 3, pp 202-204, issn 0002-0729Article

Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropeniaJAKUBOWSKI, A. A; SOUZA, L; KELLY, F et al.The New England journal of medicine. 1989, Vol 320, Num 1, pp 38-42, issn 0028-4793Article

Phase II trial of 10-deaza-aminopterin in advanced breast cancerTHONGPRASERT, S; CURRIE, V. E; BUDMAN, D et al.Cancer treatment reports. 1987, Vol 71, Num 1, pp 95-96, issn 0361-5960Article

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863VENOOK, A. P; KLEIN, C. Enders; ROSNER, G. L et al.Annals of oncology. 2003, Vol 14, Num 12, pp 1783-1790, issn 0923-7534, 8 p.Article

Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancerKREIS, W; BUDMAN, D.Seminars in oncology. 1999, Vol 26, Num 5, pp 34-38, issn 0093-7754, SUP17Article

Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following leumpectomy : a pilot trialLICHTMAN, S. M; BUDMAN, D; BOSWORTH, J et al.American journal of clinical oncology. 1991, Vol 14, Num 4, pp 317-321, issn 0277-3732, 5 p.Article

Evaluation of colonic neoplasia by flow cytometry of endoscopic biopsiesMCKINLEY, M; BUDMAN, D; CACCESE, W et al.The American journal of gastroenterology. 1985, Vol 80, Num 1, pp 47-49, issn 0002-9270Article

Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemiaDAGHESTANI, A. N; ARLIN, Z. A; CLARKSON, B. D et al.Cancer research (Baltimore). 1985, Vol 45, Num 3, pp 1408-1412, issn 0008-5472Article